Inventiva S.A.
Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.
IVA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US46124U1079
- LEI:
- Country:
- United States of America
- Address:
- 50 RUE DE DIJON, 21121 DAIX
- Website:
- https://inventivapharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's pipeline targets conditions including non-alcoholic steatohepatitis (NASH), fibrosis, and other metabolic and rare genetic disorders. Its lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial for the treatment of NASH. Following positive Phase IIb study results, lanifibranor was granted Breakthrough Therapy Designation by the U.S. FDA, highlighting its potential to address the key features of the disease, including inflammation, ballooning, and fibrosis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inventiva S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Inventiva S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inventiva S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
